Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Simpson

Showing results (171-180 of 216) with videos related to

Pageof 22
Sort By:
Neurology|December 16, 2014
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected peopleDavid B Clifford, Florin Vaida, Yu-Ting Kao, et al.
Journal of the Peripheral Nervous System : JPNS|November 21, 2023
Plasma proteomic analysis on neuropathic pain in idiopathic peripheral neuropathy patientsPerry T C van Doormaal, Simone Thomas, Senda Ajroud-Driss, et al.
Journal of Neurovirology|January 6, 2016
Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort studyEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
Neurology|May 11, 2016
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of NeurologyDavid M Simpson, Mark Hallett, Eric J Ashman, et al.
American Journal of Epidemiology|June 27, 2014
The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIVEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
The Journal of Antimicrobial Chemotherapy|November 25, 2010
Efavirenz concentrations in CSF exceed IC50 for wild-type HIVBrookie M Best, Peter P Koopmans, Scott L Letendre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2013
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorderRonald J Ellis, Scott Letendre, Florin Vaida, et al.
Journal of Neurovirology|June 13, 2015
CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV diseaseAlbert M Anderson, Christine Fennema-Notestine, Anya Umlauf, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2012
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentrationDavid Croteau, Steven S Rossi, Brookie M Best, et al.
The Lancet. HIV|June 19, 2019
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort studyAlessandro Livelli, Florin Vaida, Ronald J Ellis, et al.
Pageof 22

Showing results (171-180 of 216) with videos related to

Sort By:
Pageof 22
Neurology|December 16, 2014
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected peopleDavid B Clifford, Florin Vaida, Yu-Ting Kao, et al.
Journal of the Peripheral Nervous System : JPNS|November 21, 2023
Plasma proteomic analysis on neuropathic pain in idiopathic peripheral neuropathy patientsPerry T C van Doormaal, Simone Thomas, Senda Ajroud-Driss, et al.
Journal of Neurovirology|January 6, 2016
Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort studyEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
Neurology|May 11, 2016
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of NeurologyDavid M Simpson, Mark Hallett, Eric J Ashman, et al.
American Journal of Epidemiology|June 27, 2014
The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIVEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
The Journal of Antimicrobial Chemotherapy|November 25, 2010
Efavirenz concentrations in CSF exceed IC50 for wild-type HIVBrookie M Best, Peter P Koopmans, Scott L Letendre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2013
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorderRonald J Ellis, Scott Letendre, Florin Vaida, et al.
Journal of Neurovirology|June 13, 2015
CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV diseaseAlbert M Anderson, Christine Fennema-Notestine, Anya Umlauf, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2012
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentrationDavid Croteau, Steven S Rossi, Brookie M Best, et al.
The Lancet. HIV|June 19, 2019
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort studyAlessandro Livelli, Florin Vaida, Ronald J Ellis, et al.
Pageof 22